Watch HCWB. Know when insiders buy.
One email the day a filing lands. Free.
HCWB
HCW Biologics Inc.
2.01
−0.04 −1.95%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$5.6MNET CASH $741K52W 1.61 – 29.28SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $122K | — | -77.1% | −$3.2M | −$5.2M | — | -11.58 | −$4M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $6.5M | — | 100.5% | $3.2M | $3.5M | — | 1.39 | −$1.6M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.5M | $719K | — | 0.71 | −$3.4M | $0 | −$3.4M | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$3.3M | −$4.6M | — | -2.02 | −$3.2M | $0 | −$3.2M | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$3.5M | −$1.9M | — | -40.72 | −$3.3M | $0 | −$3.3M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$2M | −$2.2M | — | -11.80 | −$3.5M | $0 | −$3.5M | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.1M | −$3.4M | — | -2.63 | −$2.8M | $113K | −$2.9M | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$3.7M | −$3.9M | — | -4.13 | −$2.9M | $37K | −$3M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$15.1M | −$15.3M | — | -16.16 | −$4.9M | −$19K | −$4.8M | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$7.5M | −$7.5M | — | -0.20 | −$3.6M | $130K | −$3.7M | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$10.8M | −$10.7M | — | -0.30 | −$3.9M | $3.7M | −$7.6M | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$5.1M | −$4.9M | — | -0.14 | −$5.6M | $630K | −$6.2M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$13.2M | −$8M | — | -10.63 | −$13.4M | $0 | −$13.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$29.5M | −$30M | — | -30.96 | −$14.2M | $262K | −$14.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$25.7M | −$25M | — | -0.70 | −$22.5M | $6.2M | −$28.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$15.1M | −$14.9M | — | -0.42 | −$10.4M | $10.3M | −$20.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$13.4M | −$12.9M | — | -0.69 | −$11M | $47K | −$11M | — | — |
| FY2020 · to Dec 31 | $4.1M | — | −$5.8M | −$5.8M | -141.5% | -1.49 | −$10.4M | $187K | −$10.6M | — | — |
Every number comes from HCW Biologics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.